Publications by authors named "S Accassat"
Article Synopsis
- A study evaluated the eligibility of patients with cancer-associated thrombosis (CAT) for randomized clinical trials assessing direct oral anticoagulants (DOACs) against low molecular weight heparin.
- Out of 302 patients analyzed, nearly 46% for the HOKUSAI-VTE trial and 53% for the CARAVAGGIO trial had non-inclusion criteria, such as unusual site thrombosis and severe health conditions.
- The 6-month follow-up showed no significant difference in event-free survival between those eligible and ineligible for the trials, highlighting the need for more research on DOACs' safety and effectiveness for ineligible CAT patients.
Direct oral anticoagulants against activated factor X and thrombin were the last milestone in thrombosis treatment. Step by step, they replaced antivitamin K and heparins in most of their therapeutic indications. As effective as the previous anticoagulant, the decreased but persistent risk of bleeding while using direct oral anticoagulants has created space for new therapeutics aiming to provide the same efficacy with better safety.
View Article and Find Full Text PDFEffect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial.
EClinicalMedicine
June 2023
Background: Venous thromboembolism is a major complication of coronavirus disease 2019 (COVID-19). We hypothesized that a weight-adjusted intermediate dose of anticoagulation may decrease the risk of venous thromboembolism COVID-19 patients.
Methods: In this multicenter, randomised, open-label, phase 4, superiority trial with blinded adjudication of outcomes, we randomly assigned adult patients hospitalised in 20 French centers and presenting with acute respiratory SARS-CoV-2.
Background: Even though antithrombotic therapy has probably little or even negative effects on the well-being of people with cancer during their last year of life, deprescribing antithrombotic therapy at the end of life is rare in practice. It is often continued until death, possibly resulting in excess bleeding, an increased disease burden and higher healthcare costs.
Methods: The SERENITY consortium comprises researchers and clinicians from eight European countries with specialties in different clinical fields, epidemiology and psychology.